A 54-year-old female was admitted to our hospital for gingival bleeding and was diagnosed as acute promyelocytic leukemia (APL). She received induction therapy according to the AML92 protocol of the Japan Adult Leukemia Study Group (JALSG) with all-trans retinoic acid (ATRA) plus chemotherapeutic agents. She achieved complete remission, but one year later had a relapse in her external auditory canal without leukemic cell in the bone marrow. Extramedullary disease is rare in APL.This case suggests the importance of careful observation for extramedullary relapse in patients whoare treated with ATRA. (Internal Medicine 36: 484-486, 1997) 
Introduction
Differentiation therapy with all-trans retinoic acid (ATRA) has now become first line therapy for acute promyelocytic leukemia (APL), and results in greater than 80% complete remission without serious complications. ATRA differs from conventional agents by inducing differentiation of the immature malignant cells. However, there maybe some unknown problems.
Extramedullary relapse is rare in APL, when treated with conventional chemotherapy. Wereport here a patient with APL whoobtained complete remission with ATRA, but had arelapse in the external auditory canal during complete hematological remission. This is the first case of an isolated initial site of relapse in the external auditory canal, which was molecularly confirmed as PML/RARa.
Case Report
A 54-year-old womanwas referred to our hospital on May 1 8, 1994 due to prolonged gingival bleeding after tooth extraction. Her white cell count was 46.0x109// with 72%abnormal promyelocytes in the peripheral blood, and bone marrow was characteristic for APLwith 7 1 %abnormal promyelocytes and 1 %blasts. Chromosomalanalysis revealed 19 of20 metaphases tobe46XX; t(15;17) and 1 tobe46; XX. PML/RARamRNA was positive by the RT-PCR method. She received an induction therapy according to the AML92 protocol of the Japan Adult Leukemia Study Group (JALSG) with ATRA45 mg/m2 orally daily plus behenoyl cytarabine (BHAC) 200 mg/m2 for 5 days and daunorubicin (DNR) 40 mg/ m2 for 3 days intravenously (1). She achieved complete remission on day 43 and ATRAwas discontinued on day 47. From July 1, 1994, she received the first consolidation therapy with mitoxantrone 7 mg/m2daily for 3 days and continuous cytarabine (Ara-C) 200 mg/m2 for 5 days intravenously. From August 1 1, she received the second consolidation with BHAC200 mg/m2 for 5 days, etoposide 100 mg/m2 for 5 days and DNR40 mg/m2 for 3 days intravenously and 6-mercaptopurine (6-MP) 70 mg/ m2 for 7 days orally. From Sept. 20, 1994, she received the third consolidation with BHAC200 mg/m2 and aclarubicin (ACR) 14 mg/m2 intravenously daily for 7 days. She received G-CSF for severe granulocytopenia after each consolidation therapy. Then, she received three courses of maintenance/intensification therapy according to the AML92 protocol every 2 months. In June 1995, she noticed difficulty of hearing in her left ear, and otological inspection showed a tumor in the left external auditory canal ( Fig. 1 ). Biopsy showed mature and immature granulocyte infiltration which was highly suspective but inconclusive forrelapse (Fig. 2 ). Bone marrowevaluation at that time was normal with 2%normal promyelocytes and no blasts. She received the fourth course of maintenance therapy with BHAC APLRelapse in External Auditory Canal 170 mg/m2 for 5 days, ACR 14 mg/m2 for4 days intravenously, and 6-MP 70 mg/m2 for 7 days orally, and the tumor disappeared. Whenshe was admitted for the fifth maintenance/ intensification therapy on September 6, 1995, she again presented with a red colored tumor in the left external auditory canal. Biopsy showed inflammatory granulation tissue with atypical myeloid cell and PML-RARamRNAwas positive by the RT-PCRmethod; these findings were compatible with relapse. With BHAC170 mg/m2 for 5 days, DNR30 mg/m2 on days 1 and 4 intravenously and 6-MP 70 mg/m2 for 7 days orally, the tumor was reduced in size, but it increased in size again. Bonemarrowat that time had no morphologically abnormal cells, but was positive for PML-RARocmRNA.She was treated with BHAC170 mg/m2for5 days, etoposide 80mg/ m2 on days 1, 3 and 5, and vindesine intravenous 2 mg/m2 on days 1 and 8, followed by 20 Gy of local radiation therapy for 10 days, starting on November 28, 1995. Then, she was treated with idarubicin 12 mg/m2 for 3 days and BHAC170 mg/m2 for 5 days intravenously, and the second complete remission was achieved. In April 1996, she again presented with an external auditory canal tumor and 10%ofAPL cell in her bone marrow. She achieved the third complete remission with 30 Gy of local radiation therapy and ATRA45 mg/m2 orally daily. Then, she received three courses of chemotherapy with continuous Ara-C 100 mg/m2 for 5 days and idarubicin 10 mg/m2 for 3 days intravenously.
She has been in complete remission for five months.
Discussion
ATRAinduces remission by differentiation of APLcells without hemorrhagic complications; this is the primary cause of the early deaths. On the other hand, hyperleukocytosis and "retinoic acid syndrome" are well known, and are often fatal adverse effects associated with ATRAtherapy. Dermatitis, headache, gastrointestinal symptoms, bone pain, liver dysfunction and hypertriglycelidemia are other less serious adverse events. However, short since ATRAbecame clinically introduced rather recently, there may be some unexpected problems associated with this agent. Extramedullary disease has been rare in APL. Byrd et al (2) reviewed the extramedullary lesions in acute non-lymphocytic leukemia reported since 1965, and cited no APLcase among 154 well documented cases. Wehave also reviewed other literature and found 16 cases of extramedullary disease of APL from 1965 to 1995 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , and most of them were extramedullary lesions at relapse (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) Tobita et al lial adhesion and tissue migration. Giralt et al ( 16) hypothesized that with an increase in expression of adhesion molecules, ATRA treatment might be associated with an increase of extramedullary relapse. Careful observation for extramedullary relapses, especially leukemia cutis, will be necessary in patients with APLwho were treated with ATRA.
